KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

Marco Tagliamento, Marco Bruzzone, Eva Blondeaux, Filippo Dall'Olio, Mihaela Aldea, Carlo Genova, Arianna Marinello, Jordi Remon, Lizza E L Hendriks, Lucia Del Mastro, David Planchard, Fabrice Barlesi, Matteo Lambertini, Benjamin Besse

Eur J Cancer 243 116867

PMID42269244
PMCID-
DOI10.1016/j.ejca.2026.116867
发表日期2026-06-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Although first-line alectinib is highly effective, outcomes in ALK-positive NSCLC remain variable. METHODS: We conducted an individual patient-level pooled analysis of the phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials to explore new prognostic and predictive factors. The primary endpoint was PFS. Multivariate Cox and random effects models accounted for trials independence. Baseline characteristics analyzed included high vs. low tumor burden (sum of target lesions by RECIST v1.1 above/below the median) and body mass index (BMI). RESULTS: 500 patients were included (alectinib n = 249, crizotinib n = 251). Baseline characteristics were balanced between the two arms. Median follow-up was 17.1months. Alectinib compared to crizotinib improved PFS (HR 0.41, 95%CI 0.31-0.55, p < 0.001) but not OS (HR 0.80, 95%CI 0.50-1.28, p = 0.353). In the whole population, high tumor burden correlated with shorter PFS (HR 1.88, 95%CI 1.44-2.45, log-rank p < 0.001) and OS (HR 2.24, 95%CI 1.40-3.58, log-rank p < 0.001), confirmed in multivariate analysis (PFS HR 1.66, 95%CI 1.26-2.20, p < 0.001). Significant interaction was found between treatment and tumor burden in PFS cox model (p for interaction=0.002). The PFS benefit of alectinib vs. crizotinib was greater in low tumor burden (HR 0.25, 95%CI 0.16-0.41, p < 0.001) than in high tumor burden (HR 0.52, 95%CI 0.36-0.76, p = 0.001). In multivariate analysis, BMI> 25 kg/m2 (n = 144) did not correlate with PFS (HR 0.92, 95%CI 0.68-1.25, p = 0.375) but was associated with longer OS (HR 0.50, 95%CI 0.29-0.88, p = 0.025). No significant BMI-treatment interaction was observed. CONCLUSIONS: Tumor burden was prognostic and predictive in ALK-positive NSCLC. Treatment intensification may benefit patients with high tumor burden.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。